We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only bear a small substituent to maintain the inhibitory activity, position 2 is opened for extensive modification
我们报道了新型
PI4KIIIβ
抑制剂的广泛的构效关系研究。强效筛选命中的T-00127-HEV1的
嘌呤衍
生物已作为彻底研究位置8和2的合适起点。而
嘌呤支架的位置8仅可带有一个小的取代基以维持抑制活性, 2被打开以进行广泛的修饰并且可以容纳甚至被取代的苯环而不会损失
PI4KIIIβ抑制活性。这些经验观察与我们的对接研究的结果很好地相关,这表明位置2指向溶液,可以为与酶的远程残基相互作用提供必要的空间,而位置8周围的空腔则受到严格限制。